Chemotherapy-induced nausea and vomiting (CINV) is one of the commonest side-effects among cancer patients. However, there is lacking of hierarchical evidences comparing different antiemetics against highly emetogenic chemotherapy. Therefore, we conducted a network meta-analysis to investigate their comparative efficacy and tolerability. Randomized controlled trials that compared different antiemetic categories for adult highly emetogenic chemotherapy were included after searching PubMed, Web of Science, Embase and Cochrane Central. Acute-phase no emesis and no nausea were identified as primary endpoints. We made pairwise and hierarchical calculations by random-effects model. Effect sizes were presented by odds ratio and 95% confidential interval. Subgroup analysis was additionally performed. 143 randomized trials were included into pooled analysis, containing 22,776 patients and 18 antiemetic categories. 5-HT 3 RA plus corticosteroid plus NK-1 RA plus other (5CNO) displayed best protection against both acute emesis (SUCRA: 99.7%) and nausea (95.6%). 5CNO (99.7%) and 5-HT 3 RA plus corticosteroid plus other (5CO, 85.3%) topped subgroup hierarchies for no-naivety and anthracycline plus cyclophosphamide (AC)-based studies. On the other hand, 5-HT 3 RA plus dopamine RA plus other (5DO) may be best fit for delayed emesis (92.0%) and nausea (92.7%). Subgroups featuring no-naivety and AC-based trials preferred 5DO (91.9%) and 5CN (88.6%), respectively. In addition, dopamine RA plus other (DO) had the lowest incidence of TRAE in most circumstances, except for AC-based subgroup where corticosteroid plus dopamine RA plus other (CDO) preponderated (69.2%). 5CNO and 5DO should be considered as first-line regimens against highly emetogenic chemotherapy induced acute and delayed CINV, respectively.
receptors. 6 Further researches have summarized that two nervous pathways mediate the vomiting reactions in separate manners, namely peripheral and central transmissions. To be specific, peripheral transmission exclusively serves for acute CINV, where chemotherapeutic medications directly force the release of serotonin from intestinal chromaffin cells to activate the 5-HT 3 receptors at the terminal end of vagal afferents. On the other hand, central transmission is the core signaling for delayed CINV, in which emetogenic chemicals stimulate the area postrema to trigger the release of substance P from vagal nerve and then the activation of NK 1 receptors. Either pathway could converge the stimuli to brainstem region, which then processes efferent signals to induce downstream reflexes. 1, 6, 7 Therefore, based on current knowledge of mechanisms, antagonists of serotonin, dopamine or neurokinin receptor are widely prescribed, either as monotherapy or combined regimens. 1 In terms of highly emetogenic chemotherapy, the combination of serotonin receptor antagonist plus corticosteroid plus neurokinin receptor antagonist is consistently recommended by the up-to-date NCCN, 8 ESMO 9 and ASCO 10 guidelines for acute phase prophylaxis, while dexamethasone plus aprepitant is preferred in situation of delayed onset. However, novel investigations have revealed that some non-traditional antiemetics display extra prevention when added to first-line treatments, such as olanzapine of classical antipsychotics. 11 Moreover, a hierarchical comparison of different prophylactic strategies remains to be rarely discussed, leading to the absence of reliable evidence for clinical decision making.
In the past decade, network meta-analysis has rapidly emerged as a statistical tool offering therapeutic suggestions in a variety of fields. 12 It allows the synchronous ordering of optional schemes with respect to efficacy and tolerability, despite of the lack of direct head-to-head conclusions. 13, 14 This greatly makes up for the conventional method that only two-arm pairwise analysis could be simultaneously achieved. Hence, by an entire collection of applied regimens, we performed a comprehensive network meta-analysis aiming to unveil the best possible option against emesis induced by highly emetogenic chemotherapy.
Methods

Search strategy
Electronic databases of PubMed, Web of Science, Embase and Cochrane Central Register of Controlled Trials were systematically and independently checked by two of our investigators. "chemotherapy AND (nausea OR emesis OR emetic OR vomiting) AND (randomly OR randomized OR randomized)" were employed as full terms to guarantee the search sufficiency. Both abstract (including title) and main content of the preliminary records were stepwise assessed in order to maximize the selection accuracy. Meanwhile, we also collated the reference list from previous meta-analyses and considered them for further screening. Any discrepancy was settled by mutual discussion.
Selection criteria
Trials that met the following requirements were included: (i) Official publications without time (from inception to February 10, 2017) or language limitations; (ii) Randomized controlled trials concerning the antiemetic prophylaxis of chemotherapy induced nausea and vomiting; Trials were removed from pooled analysis due to the following reasons: (i) Containing children or adolescent patients (<18 years old); (ii) Containing concurrent or closely sequential radiotherapy; (iii) Containing results of anticipatory, breakthrough or refractory emesis; (iv) Containing oral chemotherapeutic agents; (v) Regimen of intravenous chemotherapy was moderately to minimally emetogenic; (vi) Repetitive contents from a single registered study; (vii) Containing undefined materials (such as herbal medicine without isolation of active substances) and non-pharmaceutical strategies (such as acupuncture, psychotherapy, etc.); (viii) Animal study; (ix). Comparisons between the same category of regimens; (x) Inadequate data for any endpoint (such as pharmacokinetics-specified analysis);
The eligibility of retrieved documents was appraised by two separate evaluators. All decisions were based on mutual consensus despite of initial disagreements.
Quality assessment
With several adapted adjustments, the revised version of Jadad's Scale assisted in quality rating of eligible trials. 15 Per study, there were four aspects of methodological design that required termwise evaluation, including random sequence production, allocation concealment, blindness and withdrawal. The scoring standard and its corresponding marks were listed in Supporting Information Table S1 . Those graded with four or more points were identified as high-quality
What's new?
What's the best way to ease the nausea and vomiting that can make chemotherapy so unpleasant? The current guidelines might be in need of an update. Here, the authors report the results of a network meta-analysis comparing anti-emetic treatments. They culled data from dozens of different studies on the effectiveness of strategies to relieve nausea and vomiting from chemotherapy, and they found that the best defense seemed to be 5-HT3 RA plus corticosteroid plus NK-1 RA plus other. Different treatments excelled against different types of nausea, though, and for delayed onset, 5 HT 3 RA plus D RA plus other gave the best results.
studies, otherwise regarded as low-quality in methodology. All disagreements were mutually discussed until consensus was reached.
Data extraction
A standardized form was predefined to help collect the original data. Two investigators independently extracted information within body text or approximated numerical values from figures when necessary. Articles written in Japanese and German were translated into English before data collection. All retrieved data were cross-checked and any inconsistency was solved by mutual discussion.
Endpoints
The baseline characteristics consisted of the following parameters: study name, publication year, source country, registry identifier, antiemetics, regimen category, sample size, mean age, sex ratio, tumor type, chemotherapeutic agent, chemotherapeutic naivety, performance scoring, history of motion sickness and drinking history (Details are described in Supporting Information). There were two primary endpoints including acute-phase no emesis and acute-phase no nausea. The acute stage was restricted to first 24 hr after chemotherapy administration (0-24 hr and occasionally 0-18 hr). 1 Since the awareness of delayed CINV began in the late 1990s, 5 early data without description of phase specificity were supposed as acute results. No emesis was defined as none emetic episode or retching appeared during certain periods of time. On the premise of comparability, some adaptive changes were made so that more equivocal studies could be enrolled (For instance, no vomiting, none or mild emetic episodes, etc). The intensity of nausea was primarily measured by visual analog scale (VAS), whose value below 5 suggested no nausea occurred. 16 Similarly, alternative definitions were also employed such as none or mild nausea, Grade 0 of nausea intensity (WHO criteria), etc. (Note: (i) Antiemetic data from the first-cycle chemotherapy was preferred across multi-cycle analysis. (ii) Among the multi-dosage comparisons, only those consistent with guideline recommendations (such as aprepitant 125 mg/80 mg) or single dose therapy (such as single-day oral 150 mg casopitant) were selected, for fear of effectiveness exaggeration.) Secondary endpoints were constituted by delayed-phase no emesis, delayed-phase no nausea and treatment-related adverse effects. In most cases, delayed phase referred to the 25-120 hr interval after chemotherapeutic management. 1 However, owing to the deficiency of united definition among ancient investigations, we also considered the data of nearby periods such as 25-72 hr, 25-144 hr, etc. Additionally, information at the worst day was utilized to represent the whole delayed period if its overall analysis was missing. To minimize the confounding impact by chemotherapeutic intervention, we selected treatment-related adverse effects as an indicator of antiemetic tolerability among enrolled patients, which merely calculated the untoward effect closely connected to antiemetics. (Concretely, constipation and headache were chosen for 5-HT 3 RA, NK-1 RA and other drugs; extrapyramidal reactions and hallucination belonged to DRA; euphora and facial flushing were corticosteroid-specific)
Statistical analysis
First, we did a random-effects pairwise meta-analysis to incorporate direct evidences. Since all studied endpoints were dichotomous variables, odds ratio (OR) with its 95% confidential interval (95% CI) were applied as effect size.
Second, a random-effects network meta-analysis was implemented on basis of frequentist model. Network metaanalysis derived indirect information from pairwise results, thereby providing hierarchical rankings of all evaluable regimens. 12, 14 As was known to all, there were two assumptions behind a successful network synthesis, namely transitivity and consistency. 17 If head-to-head outcomes of A with C and B with C were already obtained, then transitivity enabled statistical comparison between A and B. This hypothesis held only when baseline parameters were comparable across each trial. In this regard, concerns on selection bias could be largely eliminated and thus justifying statistical connections among indirect crowds. 18 Main confounders contained age, sex ratio and chemotherapeutic naivety, which were individually compared before network calculations. Meanwhile, consistency was another assumption needed to be measured. The consistency across network outcomes implicated that there was no significant difference between direct and indirect effect sizes, with regard to the same comparison. Presence of inconsistency implied that the hypothesis of transitivity might fail within studies. Among closed triangular or quadratic loops of each network, we employed a loop-specific method which evaluated mutual variance between indirect and direct estimates. Inconsistency factor (IF) was adopted as a numerical evaluator which hinted the existence of mutual inconsistency once its 95% CI excluded zero. 19 Network graphs per endpoint intuitively demonstrated the direct correlations between antiemetic regimens as well as their relative samplesizes. Besides, comparison-adjusted funnel plots were generated to gauge the possibility of publication bias inside each network. The better plots displayed symmetry, the less probably publication bias would appear. 5-HT 3 RA was selected as the common reference ahead of network analysis, since it had the most direct comparisons with other regimens. After the integrated estimates had been produced, the hierarchy for each outcome was constructed according to values of surface under the cumulative ranking (SUCRA), which compared the relative effectiveness or tolerability of target regimen to the best strategy ever in this field. 20 Hence, the closer SUCRA values approached 100%, the better a regimen would be. The global heterogeneity of each network was quantified by I 2 statistic (low-degree: <25%; moderate-degree: 25-75%; highdegree: >75%). Subgroup analysis was additionally carried out to examine whether the primary results were biased by certain baseline characteristics (chemotherapeutic naivety and anthracycline plus cyclophosphamide usage). Besides, since the potential confounding elements are too sporadically distributed, we do not choose to play commands of metaregression. In order to test outcome robustness of chief endpoints, we performed sensitivity analysis by interchanging fixed-effects and random-effects models, or removing lowquality trials. Stata version 12.0 was the statistical platform irrespective of pairwise or network meta-analysis. All routines and commands were standardly run as described elsewhere. 21 The construction and performance of the entire analysis were in line with protocols of Cochrane Handbook and PRISMA Checklist. All decisions were mutually agreed by two statisticians.
Results
Demographic characteristics
Among the 14,557 potentially eligible citations, 134 publications were eventually included into quantitative synthesis, corresponding to 143 randomized controlled trials. The selection flow-chart was depicted in Figure 1 . The majority of articles were written in English, except for one German and two Japanese literatures. All qualified trials featured long span of publication date, which could trace back to 1981. USA reported the maximum amount of investigations (n 5 30), followed by Italy (n 5 19) and Japan (n 5 16). In terms of regimen type, 5-HT 3 RA plus corticosteroid (5C) had the most frequent appearance (n 5 58), while 5-HT 3 RA (5, n 5 53) and D RA (D, n 5 45) ranked the second and third place respectively. Overall 22,776 patients underwent random assignment, individually ranging from 19 to 1,449 as sample-size. Excluding population without sex ratio description (n 5 675), female participators (n 5 12,205) had predominance against male counterparts (n 5 9,896). Most investigations did not specify tumor types (versatile, n 5 86) and cisplatin-containing regimens became the chemotherapeutic strategy of highest popularity (n 5 112). Within 94 studies, patients were recruited without previous chemotherapeutic experiences. Although relevant data were largely unavailable, the remaining studies displayed great homeogeneity concerning motion sickness or drinking history. More details of baseline features could be found in Supporting Information Table S2 . The global comparability had been achieved with respect to above-mentioned confounders including age, sex ratio and chemotherapeutic naivety, therefore, supporting the assumption of transitivity and subsequent network calculations.
Summary of methodological quality
Except for 13 randomized studies, the majority of eligible trials were judged as high-quality in methodology, among which six articles were perfectly constructed. Since our synthetic analysis emphasized random design, none of the included investigations were scoreless in terms of randomization, while nearly one third of which were scored with full credits (n 5 37). Similarly, good compliance to allocation concealment was also observed among most literatures, including 9 full-mark reports. Furthermore, non-blind method was disclosed in 16 publications due to their openlabel protocols; on the other hand, more than half of the selected studies were performed under well blindness (n 5 80). Reasons of withdrawal were beautifully stated amid each study. Overall speaking, the chosen trials were of enough quality for network statistics. The itemized scores of methodological analysis were listed in Supporting Information Table S3 .
Primary endpoint: Acute-phase no emesis Network calculation: A total of 137 randomized trials contributed to the research of acute-phase no emesis, which comprised of 16 treatment categories corresponding to 29 direct comparisons (Fig. 2) . In consideration of internal consistency, most of the closed loops indicated statistical match between direct and indirect estimates, in spite of two exceptions (Supporting Information Fig. S1 ). This hinted that the possibility of mutual inconsistency could be probably ignored. In contrast to the same reference, 5-HT 3 RA plus corticosteroid plus NK-1 RA plus other (5CNO, 99.7%) topped the SUCRA probabilities (Supporting Information Figs. S2 and S3), followed by 5-HT 3 RA plus corticosteroid plus NK-1 RA (5CN, 89.1%) and 5-HT 3 RA plus corticosteroid plus other (5CO, 86.1%), suggesting that 5CNO might be the most effective combination against early-phase emesis.
Each treatment along with its comparative odds ratio were arranged in descending order of SUCRA values (Fig. 3) Figs. S12 and S13) . Second, the elimination of low-quality trials was unable to fluctuate the network conclusion, among which 5CNO (99.5%), 5CN (88.8%) and 5CO (84.6%) still held advantages within the entire hierarchy (Supporting Information Figs. S14 and S15). Publication bias: Because of the graphical symmetry on funnel plot, we believed that there was no publication bias among included trials (Fig. 4) .
Primary endpoint: Acute-phase no nausea Network calculation: Data from 95 investigations were deemed as qualified for analysis of acute nausea prevention. 25 direct comparisons were involved in integrative calculation, pertaining to 17 prophylactic classes (Supporting Information Fig. S16 ). With the exception of one closed ring, the remaining nine triangular loops described no substantive difference between direct and indirect outcomes, implicating the inherent consistency of the endpoint network (Supporting Information Fig. S17 ). The relative availability of antiemetic regimens against acute nausea was sequenced according to SUCRA estimates, within which 5CNO (95.6%), 5-HT 3 RA plus corticosteroid plus D RA (5CD, 81.8%) and 5-HT 3 RA plus D RA plus other (5DO, 79.8%) might induce the most number of remission (Supporting Information Figs. S18 and S19). A descending order of treatment effectiveness was Figure S20 , containing a holistic one-to-one effect sizes. Generally, the heterogeneity approximated to 69.0% by I 2 metric. Publication bias: Although several dots located outside the effect size region, the majority of investigations seemed to be symmetrically distributed and therefore no publication bias was assumed inside the network (Supporting Information Fig. S33 ).
Secondary endpoint: Delayed-phase no emesis
Network calculation: The pooled rankings synthesized data from 82 original literatures, which contained 15 antiemetic combinations and 20 pairs of direct comparison (Supporting Information Fig. S34 ). Through constructing six triangular loops, statistical overlap was detected between the direct and indirect estimates, hence validating the assumption of consistency inside the network (Supporting Information Fig. S35 ). On the basis of SUCRA values, 5DO (92.0%) had the highest probability to become the optimal antiemetics against delayed emesis, followed by 5CNO (91.6%) and NK-1 RA (N, 77.8%; Supporting Information Figs. S36 and S37 ). Besides, a terraced arrangement of network effect sizes was illustrated in Supporting Information Figure S38 . The general heterogeneity across eligible studies summed up to 67.9% by I 2 measurement.
Subgroup analysis: In consideration of chemically inexperienced population, 5DO (91.9%), 5CNO (90.5%) as well as N (76.7%) remained the best possible managements for emetic remission (Supporting Information Figs. S39 and S40), whereas 5CN (96.0%), 5CD (64.8%) and 5O (63.5%) might be recommended for those with previous chemotherapy (Supporting Information Figs. S41 and S42) Publication bias: Inside the comparison-specific funnel plot, most trials were symmetrically situated in the center region of pooled effect size, graphically ruling out the possibility of publication bias (Supporting Information Fig. S51 ).
Secondary endpoint: Delayed-phase no nausea
Network calculation: 66 trials were enrolled into the network synthesis, comprising of 14 different strategies as well as 19 head-to-head comparisons (Supporting Information Fig. S52 ). Via examination of six triangular loops, statistical consistency was maintained between direct and indirect estimates (Supporting Information Fig. S53 ). Deriving from the SUCRA probabilities, 5DO (92.7%), 5CNO (88.5%) and 5CO (80.2%) tended to guard against delayed nausea most effectively (Supporting Information Figs. S54 and S55 ). Meanwhile, a panorama of efficacy hierarchy was summarized in Supporting Information Figure S56 , along with their network effect sizes. Globally, a moderate degree of heterogeneity was confirmed by I 2 value (64.4%). Subgroup analysis: First, we categorized investigations into two opposite subgroups, either featuring treatment naive or experienced subjects. Undergoing 5HT 3 RA plus D RA (5D, 95.1%), 5CNO (85.6%) and 5CO (76.2%) regimens, more untreated patients were protected from delayed nausea than remaining antiemetics (Supporting Information Figs. S57 and S58). Among those with former chemotherapeutic management, 5CD (97.6%), 5CN (81.8%) and 5C (57.4%) seemed promising to act as the firstline medications against delayed nausea (Supporting Information Figs. S59 and S60) . Besides, no significant variation on heterogeneity was obtained regardless of chemical experiences (Overall: I 2 5 64.4%; Naivety: I 2 5 64.5%; No-naivety: I 2 5 59.1%). Second, by pooling data from AC-based participators, 5CD (94.5%), 5CO (66.8%) and 5CN (55.7%) led to supreme resistance against delayed onset of nausea (Supporting Information Figs. S61 and S62 ). On the other hand, those administered with unspecific chemotherapy preferred 5DO (92.9%), 5CNO (87.9%) and 5CO (84.7%) in terms of delayed prophylaxis (Supporting Information Figs. S63 and   S64 ). Whichever of drug classifications, subgroup heterogeneity (AC: I 2 5 46.1%; No-AC: I 2 5 66.6%) was virtually identical to that of global approximation (I 2 5 64.4%). Sensitivity analysis: Although 5CNO (87.6%) and 5CO (79.4%) remained staying in the second and third places, the prime medication had changed to 5D (92.2%) by fixed-effects mode (Supporting Information Figs. S65 and S66) . Similarly, by substituting 5DO, 5D (92.4%) emerged as the first-rank antiemetics after the exclusion of low-quality records, while 5CNO (85.5%) as well as 5CO (82.4%) closely followed (Supporting Information Figs. S67 and S68 ).
Publication bias: Despite of several deviation samples, the funnel plot was demonstrated in an almost symmetrical form, thus confirming the publication homogeneity within (Supporting Information Fig. S69 ).
Secondary endpoint: Treatment-related adverse events
Network calculation: Information from 82 studies was pooled for network analysis. The network plot consisted of 15 prophylactic regimens and 21 paired comparisons (Supporting Information Fig. S70 ). There was no evidence of statistical inconsistency across seven triangular and two quadratic loops, suggesting the mutual comparability between direct and indirect estimates (Supporting Information Fig.  S71 ). Hinted by SUCRA index, D RA plus other (DO, 95.2%), placebo (P, 80.3%) and corticosteroid plus D RA plus other (CDO, 78.0%) had the least potential to trigger treatment-related adverse events (TRAE; Supporting Information Figs. S72 and S73). The entire rankings and corresponding odds ratio were described in Supporting Information Figure S74 . The overall heterogeneity was estimated to 50.1% by I 2 metric. Publication bias: Since the majority of samples symmetrically concentrated on the upper funnel plot, we believed that the probability of publication bias could be neglected (Supporting Information Fig. S87 ).
Discussion
Currently, 5CN still serves as the first-choice antiemetic for acute-phase CINV induced by highly emetogenic chemotherapy. [8] [9] [10] However, a large-scale randomized trial by Navari et al has discovered that the addition of olanzapine to 5CN could greatly enhance its prophylactic function against highly emetogenic chemotherapy, irrespective of acute emesis or nausea.
11 Consistently, our network calculation has confirmed the predominance of 5CNO inside both hierarchies of acute emesis and nausea, providing a more comprehensive and reliable evidence that 5CNO may probably supersede 5CN as the prior regimen. As the subgroup analysis indicates, 5CNO is also recommended for chemically naive patients while 5CO presents best protection among previously treated population. Furthermore, AC-specific analysis prefers 5CO as the most suitable antiemetic against acute CINV, partially conforming to 5CN in the guidelines. For those with unspecific chemotherapy, 5CNO still seems to be the most appropriate one. Mechanistically, olanzapine is a well-known antipsychotic drug whose involvement in multiple nervous pathways helps explain its synergistic impact to 5CN, including the blockade on serotonin and dopamine receptors. 11, 22, 23 Therefore, we believe that more antipsychotics or sedatives are possible to take effect in future researches. Meanwhile, although 5CN is recommended by ESMO guidelines, 9 there is no direct evidence concerning the relative efficacy between 5CO and 5CN in the setting of AC-based chemotherapy. Only two publications characterized by unspecific chemotherapy have reported that both combinations have no significant disparity in terms of acute CINV prophylaxis. 24, 25 Moreover, there is no mechanistic advantage of 5CN since the peripheral pathway is the primary signaling responsible for acute CINV, which involves serotonin receptors instead of neurokinin transduction. 1, 6 This partially supports the subgroup outcome that 5CO has the potential to displace 5CN as the top strategy for AC-specific chemotherapy.
So far, dexamethasone plus aprepitant has been regarded as the dominant combination against delayed CINV.
1 However, huge difference has been observed by our network results that 5DO is probably with the highest protective effects when delayed episodes threaten. Dexamethasone plus aprepitant is recommended based on investigations which analyze delayed results of antiemetics regardless of its acutephase management. 9 For fear of possible carryover effect by acute regimens (usually 5-HT 3 RA), we redefine the categories by taking all-phase regimens into account, which may partially contribute to the incompatibility between network and guidelines results. On the other hand, neither 5CNO nor 5CN could equal with 5DO in terms of antiemetic efficacy, although they seem more consistent with the current guidelines since dexamethasone and aprepitant have been involved. This probably hints that the altered results could not simply blame on reclassified categories, while the pharmaceutic advantages and the influence of thalidomide should be considered since it is reported to be continuously administered during the entire cycle. 26 But the therapeutic potential of 5CNO and 5CN are still noteworthy due to their close SUCRA values to that of 5DO. Meanwhile, the classic mechanism of delayed emesis is mainly attributed to central pathway with participation of substance P, which implicates a better efficacy by involving NK-1 RA.
1 Therefore the robustness of rankings needs more verification, especially among top regimens. Among untreated patients, 5DO is still the best fit while 5CN tops the hierarchy for experienced subjects. Moreover, partially consistent to aprepitant in ESMO guidelines, 9 5CN is the top antiemetic for AC-based chemotherapy, while 5CNO displays the best ranking for no-AC studies by surpassing 5DO. These subgroup results have verified the interchangeable positions among 5DO, 5CNO and 5CN. However, whether this instability is attributed to smallsample effects or just reflects the reality remains unknown, therefore more original investigations are still needed especially direct comparisons between the top strategies.
According to the overall and sensitivity analysis, DO is doubtless to present the best tolerability besides its antiemetic action. DO also induces least TRAE among untreated enrollees, while 5D obtains the fewest complaints from experienced patients. Regarding AC-based studies, CDO probably leads to the lowest incidence of side effects despite DO tops the entire hierarchy again for non-AC regimens. Thus DO seems appropriate in most circumstances, and the exceptions of nonaivety and AC-based subgroups may simply blame on the lacking of DO-specific studies since there is little overlap on side reactions between AC-based chemotherapy and antiemetics. One possible explanation of why DO features the minimal number of TRAE may be that there are merely two drug classes in this combination which intrinsically has lower probability of TRAE compared to multi-classes. And since physicians are familiar with the severe manifestation by D RA such as extrapyramidal reactions, the dosage is cautiously controlled and monitored. On the other hand, 5-HT 3 RA is a brand-new category of antiemetic with adverse reactions unspecified in earlier times and is often used in relatively higher dosage, while corticosteroid is also a well known source of side reactions. These reasons may jointly contribute to the ultimate hierarchy. Nevertheless, there are still some confusing results such as placebo and D RA has a worse tolerability than that of DO. Whether it is attributed to smallsample effect, calculation bias or contamination by chemotherapy drugs remains unclear, although DO has overwhelmed placebo and D RA in most cases. Besides, albeit not in the best position, regimens that display antiemetic preference above are in a suitable range of tolerability, which further supports their clinical application.
Despite the network meta-analysis was rigorously designed and performed, there are still some limitations within: (i) We could not figure out the source of heterogeneity by subgroup analyses, since categorizations based on either chemotherapy experiences or drug types fail to decrease the internal heterogeneity significantly. (ii) Due to the intention of our design, we could not fully guarantee the equivalency of antiemetic or chemotherapeutic details across the identical groups (such as drug subtype, time interval of administration, dosage, etc), since the whole network meta-analysis is organized by categories, not specific types. Moreover, as we have mentioned above, the definition of assessed endpoints are not fully consistent, adaptive changes have been made in some situations. (iii) Although over 140 randomized trials have been included into network synthesis, the amount of original investigations is still inadequate for several categories (e.g., There is only one article describing 5CNO). This results in the deficiency of direct comparisons on endpoints especially for subgroup analyses, which may fade the credibility and availability of our pooled evidences. In spite of such limitations, we believe that the network results could still benefit the clinical decision making towards CINV, especially with the specified evidences from subgroup analyses.
Taken together, in consideration of both efficacy and tolerability, 5CNO may be the optimal antiemetic strategy against highly emetogenic chemotherapy induced acute CINV, while 5DO serves as the most suitable combination for delayed phase.
